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Abstract 
The ability to control drug release at a specific physiological target enables the 
possibility of an enhanced therapeutic effect with reduced off-target toxic side effects. 
The discipline of controlled drug release has grown to include most areas of medicine 
with examples in the literature of targeted drug delivery to the majority of organs within 
the human body. In addition, a variety of external stimuli used to meditate the drug 
release process have also been investigated. Nonetheless, the concurrent real time 
monitoring of drug release has not been widely studied. In this manuscript, we present a 
novel micellar drug delivery system that is not only capable of releasing its cargo when 
stimulated by light but also provides a real time analysis of the amount of cargo 
remaining. Controlled drug release from the delivery system was mediated by 
physicochemical changes of a spiropyran-merocyanine photochromic dyad, while drug 
quantification was enabled using a Förster Resonance Energy Transfer (FRET) 
relationship between the photochrome and a co-encapsulated BODIPY fluorophore. 
The percentage of drug released from the delivery system was significantly greater 
(24%) when exposed to light irradiation compared to an analogous control maintained in 
the dark (5%). Furthermore, the fluorescence read-out capability also enabled the drug-
release process to be followed in living cells with a significantly reduced fluorescence 
emission observed for those cells incubated with the delivery system and exposed to 
light irradiation compared to control cells maintained in the dark. Combined, these 
results highlight the utility of this approach to theranostic drug delivery with the potential 
of light-triggered released together with a fluorescence read-out to enable quantification 
of the drug release process.  
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1. Introduction 
In order for a drug to produce a therapeutic effect, it must not only reach the site of 
action but also have the correct physicochemical properties to allow it to be absorbed at 
an appropriate concentration. In the past few decades, smart drug delivery systems 
(DDS) have evolved to deliver an appropriate dose to meet the patients needs [1]. 
Delivering the drug at a controlled rate, triggered drug release and targeted drug 
delivery are some methods that have been extensively investigated. Some examples of 
such systems include the development of biopharmaceutical systems capable of 
interacting with intracellular components that respond as a direct result to environmental 
stimuli [2] and nanoparticles that specifically bind to tumour cells using receptor targeted 
systems [3]  [4]. Among these, triggered release plays a substantial role on controlling 
timing and location of drug release, since it can be induced by several external stimuli 
acting on the intracellular vehicles response [5]. Examples of stimuli used to facilitate 
drug release are temperature [6], pH [7], magnetic field [8], electric field [9], ultrasound 
[10], enzymatic activity [11] and light [12].  
Light responsive drug release is an attractive mechanism because of the ability to 
control the spatial and temporal triggering of the release process [13]. Numerous 
examples of photochromic materials capable of transforming under the influence of 
activating radiation have been explored over recent years [14]. However, the photo 
activating ability of Spiropyran compounds was recognised as early as the1920’s [15]. 
Spiropyran can undergo a reversible response to light and chemical stimulations. The 
closed ring stable state of Spiropyran (a) can be converted to its open form, 
Merocyanine (b), when irradiated with UV light, which is converted back into its original 
state when irradiated with visible light (Figure 1).  
 
Figure 1. Illustration of the phototranformation of spiropyran (a) to its merocyanine (b) 
counterpart and subsequent movement within the micellar environment before transformation 
back under visible irradiation 
This simple photochromic transformation has found many applications ranging from 
molecular sensors [16] to DNA-based logic operations [17] and bioimaging [18].  Here, 
we exploit differences in the hydrophobic/hydrophilic balance between the two isomers 
to mediate drug release from a micellar based delivery system. The spiropyran form, 
with its hydrophobic four-ring system preferentially favours a non-polar environment 
whereas its open ring zwitterionic merocyanine counterpart prefers a more hydrophilic 
environment. 
In addition to the triggered delivery mechanism there are also a number of 
considerations to make when selecting the type of DDS. More than 40 % of newly 
discovered drugs have little or no aqueous solubility (as determined by the 
Biopharmaceutical Classification System): 90 % of drugs approved since 1995 have 
poor aqueous solubility, poor permeability or both [19]. The delivery of hydrophobic 
drugs can be achieved in a number of ways. For example, a pro drug of the active 
compound may be prepared to catabolize to the original drug. Alternatively, a specific 
functional group can be altered to create a synthetic analogue with more appropriate 
hydrophilicity, or the compound may be formulated in such a way as to enable delivery 
by enteric coating for oral delivery or by an alternative method such as rectal or 
intravenous administration. All of these approaches have proven successful in 
delivering hydrophobic compounds.  However, these approaches can often lead to 
enhanced first pass effects and thus the requirement for higher dosage or enhanced 
expense or, depending on the dosage form, poor patient compliance.  
An alternative and successful method for the delivery of hydrophobic drugs is the use of 
polymeric drug delivery systems. These DDSs can be formulated as, micelles [20], 
liposomes [21], nanofibers [22], dendrimers [23], colloids [24] or carbon nanotubes [25] 
with the majority of them falling into the category of nanoparticle drug delivery vehicles. 
It has been suggested that the polymeric nano carriers can become concentrated 
preferentially in tumors, inflammatory sites, and at antigen sampling sites by virtue of 
the enhanced permeability and retention (EPR) effect of the vasculature [26]. Once 
accumulated at the site, these polymeric drug delivery vehicles can act as a drug depot, 
providing a source of API to be released as and when required. This leads to enhanced 
bioavailability, sustained/controlled release and decreased toxicity caused by potential 
burst release of the API. There are numerous examples where polymeric compounds 
are shown to enhance drug delivery [27]. Among these systems Polyethylene glycol 
(PEG) is frequently used as a polymeric component. We have previously developed a 
PEG-micellar DDS and determined the size of our PEG copolymers to have an average 
hydrodynamic diameter of 26 nm [18]. As a direct result of their size, these micelles can 
navigate through the endothelium in inflammatory sites, epithelium tumors or penetrate 
micro capillaries, allowing for uptake by a variety of cell types. We have previously 
shown these micelles to efficiently cross the cell membrane of Chinese hamster ovarian 
cells and distribute themselves in the cytosol.  
Finally, the ability to quantitatively monitor the amount of drug release, from a DDS in 
real time using a simple but effective approach is an essential companion in the 
advance towards second-generation health care. To this end, there have been a 
number of examples where mesoporous silica nanoparticles (MSN) have been used as 
a cage for drug delivery with the drug co-incorporated alongside a photochromic 
compound [28], an oligonucleotide containing a recognition element [29] or a redox 
active FRET pair [30] so that the system operates like a molecular valve. In each case, 
the drug was prevented from exiting the pores of the NP due to the large bulky groups 
surrounding the MSN. On application of external stimuli, the outer layer (valve) was 
disrupted and the inner cargo released from the MSN. In addition to the triggered 
release, a Förster Resonance Energy Transfer (FRET) mechanism was utilised to 
enable real time monitoring of drug release.  
In this manuscript, an alternative approach has been developed that combines a 
triggered release of hydrophobic drugs encapsulated within a polymeric micellar drug 
delivery system with real time analysis through molecular communication. This was 
achieved using a FRET mechanism whereby a FRET pair was contained within the 
hydrophobic interior of a self-forming amphiphilic micelle. Upon application of an 
external UV light trigger, one of the FRET pair, a Spiropyran moiety, undergoes a photo 
transformation to the more hydrophilic merocyanine isomer and transcends the micellar 
membrane into the aqueous external environment. The other half of the FRET pair, a 
hydrophobic bodipy fluorochrome, remains within the non-polar environment of the 
micelle. Thus, release of the merocyanine isomer from the micelle modulates the donor-
acceptor energy transfer process enabling the release process to be followed by 
fluorescence spectroscopy, illustrated in Figure 2.  A decrease in the quenching ability 
of the merocyanine for the bodipy emission is observed relative to the amount of 
merocyanine remaining within the micellar structure. 
 
Figure 2. Schematic representation of the UV triggered release caused by the photoisomerism 
of Spiropyran to the zwitterionic Merocyanine transcending the amphiphilic micelle and 
concomitant quantification using FRET with the simulated emission of the Bodipy donor moiety.  
Indeed, the scope of this approach can be further extended by conjugating an Active 
Pharmaceutical Ingredient (API) onto the Spiropyran isomer enabling its release to be 
controlled and monitored in real time. To illustrate this, we have attached ibuprofen to 
spiropyran using an ester linkage, determined the release of this conjugated ibuprofen-
spiropyran compound from the micelle upon UV light irradiation and compared these 
results to the release of unmodified spiropyran from the micelle.   
2. Materials and Methods 
2.1. Materials 
All reagents and solvents were purchased from Sigma-Aldrich and used without further 
purification. 2,3,3-trimethylindolenine 98%, 1-bromodecane 98%, 2-hydroxy-5-
nitrobenzaldehyde 98%, Piperidine ≥99.5%, 2-bromoethanol 95%, Potassium Hydroxide 
85% KOH Basis, Triethylamine ≥99%, Boron Trifluoride ≥99.5%, Trifluoroacetic Acid 
99%, 2,3-Dichloro-5,6-dicyano-p-benzoquinone 98%, 4-Formylbenzoic acid 97%, 2,4-
Dimethylpyrrole 97%, Phosphate Buffered Saline Tablets , Dialysis tubing cellulose 
membrane flat width 10 mm, Ibuprofen,   4-(dimethylamino)pyridine, N,N′-
Dicyclohexylcarbodiimide, Chloroform, Acetonitrile, Ethanol, Dichloromethane, Diethyl 
Ether , Hexane, Ethyl Acetate, Tetrahydrofuran. 
2.3 Synthesis of compounds 
The synthesis of hydrophobic spiropyran 1'-decyl-3',3'-dimethyl-6-nitro-spiro[chromene-
2,2'-indol-1-ium] (HSP) (4) has been previously described [18].  
2.3.1 Synthesis of (10-(4-(decylcarbamoyl)phenyl)-5,5-difluoro-1,3,7,9-tetramethyl-
5H-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide) (3)  
Compound 3 was synthesized following a two-step procedure as detailed below.  
Step 1: Synthesis of (10-(4-carboxyphenyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-
dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinin-4-ium-5-uide) (1) (S1) 
To a solution of 4-formylbenzoic acid (0.5 g, 3.3 mmol) and 2, 4-dimethylpyrrole (0.69 g, 
7.3 mmol) in THF (90 mL) was added several drops of trifluoroacetic acid. The mixture 
was stirred at ambient temperature overnight, then a solution of 2,3-dichloro-5,6-
dicyano-p-benzoquinone (0.75 g, 3.3 mmol) in THF (120 mL) was added. The mixture 
was stirred continuously for another 4 h. After the addition of triethylamine (18 mL, 0.13 
mol), BF3·OEt2 (18 mL, 0.15 mol) was added dropwise to the mixture, which was cooled 
in an ice-water bath. The mixture was kept stirring at ambient temperature overnight, 
then filtered through a celite pad. The residue was washed with CH2Cl2 (ca. 50 mL), 
then the combined filtrate was rotary evaporated to dryness. The residue was 
redissolved in CH2Cl2 (100 mL) and the solution was washed with 5% aqueous NaHCO3 
solution (100 mL) followed with water (100 mL × 2). The organic portion was dried over 
anhydrous MgSO4, then evaporated in vacuo. The crude product was purified by silica 
gel column chromatography using CH2Cl2/MeOH 99/1 as the eluent to give 1 as an red 
solid (0.615 g, 51%) (S2). 
Step 2: Synthesis of compound 3 (Scheme 1) 
A mixture of 1 (127 mg, 0.34 mmol), dodecylamine 2 (45 mg, 0.28 mmol), EDC (110 
mg, 0.57 mmol), and DMAP (7 mg, 0.056 mmol) was dissolved in 20 mL of CH2Cl2. 
After stirring at 27 oC for 1 h in the dark the solvent was removed under vacuum. The 
obtained crude product was purified by column chromatography (hexane/EtOAc 1:1) to 
give 160 mg of 3 as a orange oil (yield 91%).1H NMR (CDCl3, 500 MHz): δ = 7.91 (d, J = 
8 Hz, 2H), 7.39 (d, J = 8 Hz, 2H), 6.18 (br s, 1H), 5.98 (s, 2H), 3.49 (t, J = 6 Hz, 2H), 
2.55 (s, 6H), 1.65 (m, 2H), 1.4-1.2 (m, 14H), 1.35 (s, 6H), 0.87 (t, J = 6.5 Hz, 3H); 
ESIMS: m/z 506 [M-1]-. 
 
Scheme 1. Amidation of Bodipy compound 1 to increase the hydrophobicity of compound 3 
2.3.2 Synthesis of Spiropyran compound 2-(3',3'-dimethyl-6-nitro-spiro[chromene-
2,2'-indol-1-ium]-1'-yl)ethyl 2-(4-isobutylphenyl)propanoate (8) 
 
 
The synthesis of compound 8 (SP-IB) was a two-step process. The intermediate 
compound 2-(3',3'-dimethyl-6-nitrospiro[chromene-2,2'-indolin]-1'-yl)ethanol (6) was 
prepared following a literature procedure [31] (S3). The SP-IB was synthesized by a 
modified method from Baumann et. al. 2013 [32]. Synthesis of SP-IB 8 is detailed in 
Scheme 2. A mixture of 6 (100 mg, 0.28 mmol), Ibuprofen 7 (70 mg, 0.34 mmol), EDC 
(108 mg, 0.56 mmol), and DMAP (7 mg, 0.056 mmol) was dissolved in 20 mL of CH2Cl2. 
After stirring at room temperature for 1 h in dark, the purple solution becomes colorless 
and solvent was removed under vacuum. The obtained crude product was purified by 
column chromatography (hexane/EtOAc 4:1) to give 145 mg of 8 as a green oil (yield 
94%).1H NMR (CDCl3, 500 MHz): δ = 7.99-7.94 (m, 2H), 7.18 (t, J = 7.0 Hz, 1H), 7.14-
7.12 (m, 2H), 7.07-7.06 (m, 3H), 6.89 (t, J = 7.0 Hz, 1H), 6.79-6.66 (m, 2H), 6.26 (d, J = 
6.5 Hz, 1H), 5.62 (t, J = 11.0 Hz, 1H), 4.22 (m, 2H), 3.63 (m, 1H), 3.45-3.31 (m, 2H), 
2.44 (t, J = 6.0 Hz, 2H), 1.83 (m, 1H), 1.45 (dd, J = 21.0 Hz, J = 7.0 Hz, 3H), 1.23 (s, 
3H), 1.06 (d, J = 22.0 Hz, 3H), 0.90 (d, J = 6.5 Hz, 6H); ESIMS: m/z 541 [M+H]+. 
 
 Scheme 2. Synthesis of Spiropyran compounds hydrophobic spiropyran (HSP) (4) and 
Ibuprofen spiropyran (IBSP) (8).  
2.4 Preparation and characterisation of micelles 
The synthesis of the random co-polymer has been extensively described previously by 
the authors as both a hydrophobic [18] and hydrophilic [33] drug carrier and was 
prepared without further modification. It was comprised of two monomers (polyethylene 
glycol (PEG) (Mn 500) and a decyl chain (C10)) both containing a methacrylate 
functional group and polymerized using a free radical initiator in a 5: 3 molar ratio of 
PEG:C10 (scheme displayed in S5). The polymer has previously been determined to be 
biocompatible with negligible toxicity at the concentrations used. Micelles were prepared 
by evaporating the desired amount of polymer in CHCl3 in a round bottom flask along 
with 3 and 4 or 8 to form a thin film. The resultant film was hydrated with PBS to form 
the micelles. Micelle size, polydispersity index and zeta potential was analysed by 
dynamic light scattering using a Malvern Nano-ZS Zeta sizer. Particle morphology was 
observed by scanning electron microscopy (SEM) at high vacuum mode using FEI 
Quanta ESEM. A particle suspension was air dried for 24 hours on stainless steel stubs 
and further coated with ultra-thin Gold/Palladium layer at 18mA for 3 minutes using 
Polaron Equipment Ltd E5100 Sputter coater and observed.  
 
2.5. Evaluation of phototransformation of 4a to 4b 
0.5mL 4a (0.1 mg mL-1) was added to 0.6 mL polymer (2.5 mg mL-1) and evaporated 
into a thin film and hydrated with 3mL PBS to form micelles. These samples were 
irradiated from a fixed distance of 4 cms at 365 nm (0.4 mW cm–2) with a Mineralight 
UVGL–25 lamp (UVP 95-0006-03 Model UVL-56 6 Watt).  The UV-Vis  spectra was 
recorded using a Varian Cary Eclipse UV spectrophotometer at intervals of 30 seconds 
for 6.5 minutes until no further increase in absorbance of 4b (560nm) was observed.  
2.6. FRET efficiency  
Micelles were prepared as described in section 2.4 with 78 µL of 3 (0.08 mg mL-1) and 
varying volumes of 4 (0.2 mg mL-1) to obtain molar ratios 1: 0.5-10 of 3:4 and hydrated 
with 3 mL PBS to form micelles. The FRET efficiency was determined by allowing the 
photo-transformation of 4a to 4b while the concentration of 3 remained constant. 
Fluorescence emission spectra of 3 were recorded (Ex 525nm Em 545 nm) before and 
after UV light exposure using a Varian Cary Eclipse Fluorescence spectrophotometer.  
2.7. In vitro triggered release 
Micelles were prepared as above using 0.176 mL of 3 (0.2 mg mL-1) with 0.6 mL of 4 
(0.5mg mL-1) and 2mL polymer (2.5mg mL-1) and hydrated with 2mL PBS. Release 
studies were undertaken using Franz diffusion cells and dialysis membrane (MWCO 
14,000). 200 µL of the micelle formulation was loaded into donor compartment while the 
acceptor chamber comprised of PBS and maintained at 37oC. The contents of the donor 
chamber were irradiated with UV light for fixed time periods of 2, 4, 6, 8, 10 and 12 mins 
and solutions were analysed using fluorescence spectroscopy at Ex360nm-EM 637nm. 
Similarly, control studies were conducted in the absence of UV light. For determining 
stability and reproducibility of the system, micelles containing 3 and 8 were loaded onto 
Franz diffusion cells and subjected to cycles of 5 minutes UV light and 20 minutes dark 
conditions during which samples were scanned for fluorescence emission of 3 at Ex 
525nm-Em 540nm at 5 minutes intervals for 20 minutes.  
2.8 Observation of FRET in HeLa cells  
HeLa cells were incubated in modified DMEM with 10% FBS and 1% Pen/strep in 96 
well plates at a cell density of 5x103 cells in each well and allowed to adhere overnight. 
When 60 % confluency was reached, 2 mL micelle solutions were prepared containing 
either 3 (0.176mL of 0.2 mg mL-1) and 4 (0.6mL of 0.5mg mL-1) or just 3 (0.6mL of 
0.5mg mL-1). 50µl of this solution were added to the wells and incubated for 18 h. The 
cells were then washed twice with PBS and the fluorescence emission determined 
using an ELISA plate reader (Ex 485nm and Em 520nm). For confocal microscopy, cells 
were treated as mentioned above and imaged using a Leica DMI6000b inverted 
microscope with a 40x oil immersion lens. All images were analysed using LAS AF 
v2.3.6 software. 
2.9 Comparative release study to quantify triggered release by FRET 
Release studies were conducted on Franz diffusion cells using dialysis membrane. 
Briefly micelles loaded with 3 and 8 were loaded into acceptor compartment and the 
donor compartment was filled with PBS maintained at 37°C. Micelles were irradiated 
with UV light for 5 minutes after which they were subjected to light and dark conditions 
for 20 minutes. Samples were taken at 5 minute interval and observed for UV 
absorbance at 345nm for 8a and fluorescence emission of 3 following a 20 minute 
equilibration period in visible light conditions. Similar studies were conducted without UV 
trigger. 
 
3. Results and Discussion 
3.1. Synthesis of compounds 
The synthesis of compound 1 was achieved by the synthetic procedure outlined in 
Scheme S1 (Supporting information). Successful product formation was confirmed by 
mass spectroscopy and 1H NMR spectroscopy. Compound 3 was synthesized to 
increase the hydrophobicity of the FRET donor and hence ensure continued 
encapsulation within the micelle. Synthesis was achieved by a modification of a 
previous procedure [18] with characterisation detailed in section 2.3.1. Compound 4 
was synthesized as described in scheme 2 and again successful product formation was 
confirmed by 1H NMR and mass spectroscopy. Compound 8 is a novel compound and 
was formed by an esterification between 6 and 7 in a 1:1 stoichiometry with a yield of 
94%. Successful product formation was again confirmed by 1H NMR and mass 
spectroscopy, as detailed in section 2.3.2.  
 
3.2. Preparation and characterisation of micelles 
DLS measurements of micelles loaded with 3 and 4 indicate an average particle size of 
27.5 ±0.98 nm with PDI 0.416 ±  0.009 and surface charge of -1.67 ± 0.73 as 
determined by zeta potential measurements. These observations were in agreement 
with those observed previously by Yildiz et al using the same polymeric micelle with 
encapsulated cargo [18]. However when 4 was replaced by 8, the micelle size 
increased to 45.93 ± 2.72  nm and PDI was 0.346 ± 0.04 with -2.05 ± 0.61 zeta 
potential. This slight increase in micelle size may be attributed to the greater rigidity of 8 
causing a larger hydrophobic internal core within the micelle. There was no major 
change in the PDI and zeta potential values for micelles following encapsulation with 
regards to content indicating successful incorporation of 8 inside the micelle. Figure 3a 
shows a representative particle size distribution graph for micelles loaded with 3 and 4, 
while a scanning electron microscopic image of micelles loaded with 3 and 8 (Figure 3b) 
show well-formed particles with spherical morphology. 
 Figure 3. A. Dynamic light scattering displaying the hydrodynamic radius of micelles. B. SEM 
image of micelles 
3.3. Quantification of photo physical transformation of 4a to 4b 
For efficient FRET to occur between a donor-acceptor pair two main criteria must be 
met. First, the donor and acceptor molecules must be in close proximity to each other 
and secondly, the emission spectrum of the donor must overlap effectively with the 
absorption spectrum of the acceptor. In the context of the micellar delivery system 
described above, as both the donor and acceptor are originally confined within the 
micelle, a nanoscale distance between the two molecules can be guaranteed. [34]. In 
terms of spectral overlap, the absorbance spectrum of 4a encapsulated within the 
micelle was determined to have a maximum absorbance centered at 360nm. Upon 
activation by UV light, 4a undergoes a ring opening of the spiro carbon to its 
corresponding merocyanine, 4b (Figure 1). The merocyanine is zwitterionic, and 
therefore more hydrophilic. It has also an elongated area of conjugation and therefore 
induces a significant bathochromic shift to a new absorbance maximum at 550nm which 
coincides with the emission wavelength of 3 (Figure 4) when excited at 525 nm.  
 Figure 4. Absorbance spectra of 4a and following photoconversion to 4b with the emission 
spectra of 3 with Ex 525 nm. 
This spectral cohesion of absorbance and emission of 4b and 3 is imperative for energy 
transfer from 3 (the fluorescent donor) and 4b (the photochromic acceptor. 
Nevertheless, the time required for conversion of 4a to 4b can significantly affect the 
energy transfer from 3 to 4b. Hence we irradiated 4a with UV light and monitored the 
UV-Vis spectrum at increments of 30 seconds in aqueous medium and found that it 
required 5 minutes irradiation for complete conversion from 4a to 4b as shown in Figure 
5.  
 
Figure  5. Absorbance spectra of 4b at λmax 550nm increasing with increasing exposure to UV 
light of 365nm. Spectra displayed following exposure to 0, 0.5, 1.0, 1.5,2,  2.5, 3, 3.5, 4, 4.5, 5, 
5.5, 6 and 6.5 mins UV light at 465 nm from a fixed distance. 
After 5 minutes, the absorption reached a plateau beyond which there was no increase 
in the absorption intensity. However complete conversion of 4a to 4b took 12 minutes in 
DMF medium which can be explained by the polar nature of 4b enabling faster 
conversion in aqueous medium (S4). The polar nature of 4b is fundamental to 
encourage its release from within the micelle to the surrounding polar aqueous 
environment, enabling a triggered release of micellar content.  
3.4. FRET efficiency between 3 and 4b 
In order to identify the ratio of 3 to 4b which allows maximum energy transfer between 
the fluorophore and photochrome, the two compounds were encapsulated into the 
micelles at different molar ratios and the observed decrease in fluorescence emission of 
3 following  irradiation withUV light for 5 minutes to facilitate the conversion of 4a to 4b. 
Figure 6 shows the emission profile of 3 at varying ratios of 4b. As expected, the 
emission of 3 was highest when there was no 4b present in the micelle (spectrum a). As 
the concentration of 4a in the micelles increased, more 4a was converted to 4b upon 
irradiation with UV light and quenched the emission of 3 at 540nm proportionately 
(spectra b-h).In addition, emission from 4b at 637nm was observed to increase upon 
increasing 4a concentration indicating a successful energy transfer between 3 and 4b. 
However, the plot of percentage depletion in fluorescence emission of 3 (Figure 6 
insert) shows that a plateau was reached after a ratio 1:6 of 3:4b suggesting a 
saturation concentration was reached with no more 3 available for energy transfer. This 
suggests that the optimal FRET molar ratio between donor and acceptor to allow for 
quantitative analysis is 1:6. This is reflective of the difference in extinction coefficient 
between our donor and acceptor moieties. This was the ratio chosen for all subsequent 
studies. 
 Figure 6. Fluorescence emision of 3 following exposure to varying molar ratios of 4a and 
photoconversion to 4b. a: no UV exposure and b-h: solutions were exposed to 5 mins UV light 
at 365 nm from a fixed distance and molar ratios of compunds bodipy 3 : merocyanine 4b  1:0.5; 
1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 consecutively. Insert: FRET efficiency of 3 and 4 following 
exposure to 5 mins UV light at 365 nm from a fixed distance. Concentration of 3 remains 
constant at 3.64 µM. Percentage efficiency was determined by the relation depletion in the 
emission of 1 at 545 nm, n = 3. 
3.5. In vitro triggered release  
UV light acts as a trigger for photoinduced transformation of 4a which is hydrophobic 
with a closed ring system to an open ring 4b which is polar in nature with higher 
solubility in aqueous medium. The hydrodynamic properties of micelles allows 4b to 
easily come out of the system permitting release of encapsulated cargo. Continuous 
photoactivation of 4a within the micelle lead up to 24% release of 4b into the 
surrounding environment within 12 minutes which was significantly higher than the 5% 
release in the absence of photoactivation as seen in Figure 7. This design of a triggered 
fast release system is essential for successful release of drugs attached to 4 for 
therapeutic applications. 
 Figure 7. In-vitro triggered release of 4b from micelles after continuous activation with UV light 
for 12 minutes and no UV activation. ** indicates p<0.005. 
3.6. Reproducibility of system 
The integration of photoswitchable assemblies with fluorophores capable of resonance 
energy transfer allows the formation of a system which has the ability to switch on and 
off on demand. Figure 8 shows the fluorescence emission of 3 in the presence of 8 and 
subsequent photochromic switching between the spiropyran form (8a) to its 
merocyanine counterpart (8b) indicating the reproducibility of the system.  
 
 Figure 8. Bar chart: Fluorescence emission of 3 within micelles loaded with 8a following cycles 
of UV exposure (365 nm, 5 mins) leading to conversion of 8a to 8b and subsequent resting time 
in dark conditions permitting reversion of 8b back to 8a. Line graph: control with micelles 
containing only 3.Insert: % quenching of 3 following UV irradiation. ** indicates p<0.005 
Compound 8 was created as a prodrug, to contain an API (Ibuprofen) covalently linked 
to the photochromic spiropyran moiety. Once released from the internal core of the 
micelle it is anticipated that it would be subjected to hydrolysis via esterase’s enzymes 
and hence release the API.  When there was no 8b present in the system (in the 
absence of UV light), there was a significantly high emission of 3.  This emission was 
quenched upon photoactivation of 8a to 8b as the absorption signature of 8b overlaps 
with emission signature of 3. As 8b slowly reverted back to 8a owing to its reversibility in 
heat and visible light conditions, the emission of 3 slowly increased. The hydrophilic 
nature of 8b encourages it to transcend the hydrophobic internal core of the micellar 
system into the wider aqueous environment. Although the system was kept in the dark, 
there were three cycles of 5 minute irradiation, allowing for significant movement 
outside the micelle. This movement was observed as a decrease in the quenching 
efficiency of 3 upon subsequent photoactivation cycles (Figure 8 insert) as less 8b was 
present within nanoscale distance for FRET to successfully take place between the two 
molecules in each subsequent excitation. This decrease in the quenching of emission of 
3 is of similar magnitude to the % release of internalised compound 4, observed in 
Figure 7, with 19% release after 10 minutes of 8 when compared to the 15 % release of 
4 after 10 minutes displayed in Figure 7. The increase in release is attributed to the time 
lapse between UV stimulation and subsequent photoconversion allowing for more 
hydrophobic 8b to leave the micelle. It is seen from Figure 8 that a further fluorescence 
quenching of 74.4 % is recorded after 15 mins UV irradiation and would suggest that 
25.6 % of 8 has been released. A similar effect was seen in light conditions, but the % 
of quenching of 3 was slightly less, due to the faster photoconversion back to the 
original more hydrophobic spiropyran moiety (8a), ensuring that less compound was 
released and hence more available for the subsequent energy transfer to the donor 
(S6). Micelles loaded with only 3 did not show any changes in fluorescence emission 
after photoactivation and after subsequent resting periods, in addition there was limited 
photobleaching of 3 after UV irradiation. 
3.7. Observation of FRET in HeLa cells 
Encapsulation of cargo within micelles enables them to be transported across the cell 
membrane leading to better cellular uptake owing to their biocompatibility and size. In 
order to determine the feasibility of communication and triggered release from within the 
micelles, we incubated HeLa cells with micelles loaded with 3 and 4a and enabled the 
photoconversion of 4a to 4b present within the cells to confirm FRET communication 
between 3 and 4b. As seen in Figure 9, fluorescence emission of 3 fluctuated drastically 
according to status of 4b present within the cells, as a direct result of molecular 
communication between them. The ability of 4b to switch back to 4a in the presence of 
visible light broke the communication between 3 and 4b allowing the emission of 3 to be 
observed. These results in HeLa cells support our previous observations in vitro 
conditions in section 3.6. It can be seen that immediately following 5 minutes UV 
irradiation there is a 82.5 % quench in the fluorescence emission of 3, attributed to the 
energy transfer to the acceptor moiety, 4b. Upon subsequent photoactivation cycles of 
4b there was significantly less quenching of the emission from our donor compound 3 
(75.3% and 64.2% respectively).  This can be attributed to the more polar 4b form 
leaving the micelle DDS (24.7% and 35.8 % released after 10 and 15 minutes 
irradiation). 
 
Figure 9. Bar chart: Fluorescence emission of 3 in HeLa cells incubated overnight with micelles 
loaded with 3 and 4a and following cycles of UV exposure (365 nm, 5 mins) leading to 
conversion of 4a to 4b and subsequent resting time in visible light conditions permitting 
reversion of 4b back to 4a. Line graph: control using micelles containing 3 only. Insert: % 
quenching of 3 following UV irradiation. ** indicates p<0.005, * indicates p<0.05. 
 As expected the emission of 3 lapsed back faster in visible light conditions compared 
with dark conditions (S7), further confirming that the photoconversion of 4b to 4a is 
faster in the presence of visible light and is indirectly communicated in the form of 
higher emission of 3. Additionally, the quenching effect after subsequent UV irradiation 
cycles in the dark was similar to that seen in light conditions. Similarly, observations of 
cells by confocal microscopy indicated significant reduction in fluorescence emission of 
3 on photoactivation of 4b confirming its presence within cells (Figure 10). 
 
Figure 10. Confocal microscopic images of HeLa cells incubated with micelles loaded with 3 
and 4a showing (a) Clear field (b) Fluorescence emission of 3 (Ex 514nm, Em 520-590nm) 
before UV exposure (c) Fluorescence emission of 3 after UV exposure (365nm, 5 mins). 
3.8. Real time quantification of encapsulated cargo 
The photoswitchable nature of 8 and its molecular communication with 3 can prove 
beneficial in real time quantification of release of encapsulated materials from within the 
micellar environment. To quantify this occurrence, micelles loaded with 3 and 8 were 
loaded on to dialysis membranes in Franz diffusion cells and photoactivated for 5 
minutes to allow conversion of 8a to 8b resulting in its release from the micellar 
environment recorded over 20 minutes of resting time in both dark and visible light 
conditions. Two parameters were measured simultaneously at various time points in an 
attempt to correlate the communication seen through 3 with release of 8.  This was 
achieved by monitoring the amount of 8a present within the micelles by absorbance at 
345 nm. Following removal of the sample for analysis a set period of 20 minutes was 
observed with the sample subjected to visible irradiation, to ensure that all 8 was in the 
spiropyran form, 8a.  The results of the depletion in 8a absorbance can be seen in 
Figure 11a. The simultaneous measurement of bodipy emission (3) was collected, 
following the original 5 mins UV irradiation, each sample removed for analysis was 
subjected to 20 minutes visible light before the emission of 3 was recorded, the 
decrease in quenching is plotted in Figure 11b. From Figure 11 a good correlation is 
seen between both the fluorescence increase from 3 and the absorbance of 8a. The 
largest magnitude of change is observed from the UV stimulation in dark conditions, this 
is expected as 8b would favour the more polar environment.  Specifically, a 8.4% 
decrease in 8a absorbance is observed after 10 minutes, indicting a transfer of 8 across 
the dialysis membrane. This is indirectly communicated through a 7.0 % increase in the 
fluorescence emission of 3 (figure 11b). Similarly a 17.4 % decrease in absorbance of 
8a is seen at 20 minutes compared to 11.6 % increase in fluorescence emission of 3 at 
the same time point. Visible light conditions led to conversion of 8b back to 8a leading 
to lesser release of only about 7% from micelles which was reflected as approximately 
4% increase in fluorescence emission of 3. However there was negligible release in the 
absence of a UV trigger and is suitably revealed as insignificant increase in 
fluorescence emission of 3. This close correlation between the FRET communication 
when compared to the direct measurement of remaining spiropyran would suggest that 
there is indeed potential to further develop these smarter DDSs. 
 
Figure 11. (a) In vitro release of 8a from micelles with and without UV trigger and subsequent 
resting time in dark and visible light conditions measured by decrease in UV absorbance at 345 
nm. (b) Observation of % increase in fluorescence emission of 3 at Ex 503 Em 514 nm 
measured concomitantly with release of 8a. ** indicates p<0.005, *** indicates p<0.0005. 
4. Conclusion 
The number of smart DDSs capable of real time communication with concomitant 
stimulated drug release is increasing in response to the nanotechnology revolution [35]. 
The need for variation between the mechanism of stimulus, as well as the parameter 
involved in communication is paramount to the success of these advanced materials so 
to allow these nano-platforms to reach the full echelon of their potential. Recent 
examples illustrating this diversity can be seen by Huang at el. [36] whereby they have 
incorporated the anticancer agent doxorubicin into a supramolecular nanoparticle and 
also double up its use as the FRET acceptor to allow self-communicating. Another 
interesting example is seen by Du et al. [37] and their incorporation of five stimuli 
responsive moieties on to their NP. 
We have designed a photo-activated DDS capable of real time communication using the 
photochromic properties of spiropyrans and exploiting the differences in physiochemical 
properties. By adopting a prodrug approach, we have developed an ibuprofen-
spiropyran analogue, which has displayed significant stimulated release from within a 
micelle environment. In addition, with the incorporation of a hydrophobic bodipy 
compound within the micelle hydrophobic core, we have created a FRET 
communication between the two species present within the micelle that has shown 
significant potential for real time analysis of content. In vitro analysis has confirmed this 
system remains intact within Hela cells. This smart DDS has the potential to be adapted 
for a number of different API, by simply linking the API with the spiropyran through an 
ester or potentially an amide bond, thus increasing application for such nanoplatforms to 
include a large number of drugs with the only prerequisite being that they contain a 
suitable reactive functional groups.  
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